ECCO 2017 | Innovations in ovarian cancer treatment: PARP inhibitors

Werner Lichtenegger, MD, PhD from Charité University Hospital, Berlin, Germany, highlights innovations in gynecological cancer treatment at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He discusses new PARP inhibitors olaparib and niraparib and their respective benefits. Treatment with both olaparib and niraparib improves progression-free survival (PFS), and particularly in ovarian cancer patients with BRCA mutations and HR-deficiency induces selective cell death of cancer cells. Prof. Lichtenegger points out that interestingly niraparib is also effective in patients without BRCA mutations.